2138cn太阳集团古天乐(中国)有限公司

A Global Innovation-driven Pharmaceutical
and Healthcare Industry Group
  • 39,005 Million
    FY2021 Revenue
  • 3,277 Million
    FY 2021 Net Profit Attributable to Shareholders of the Listed Company After the One-off Gain
  • 4,975 Million
    FY 2021 R&D Expenditure
  • 36,279
    Global Employees
  • Five-Star (Excellence)
    2021 Corporate Social Responsibility Report Rating
  • BBB
    MSCI ESG Rating
As of December 31, 2021
Unit: RMB million
  • Artesun® (Artesunate for Injection)

    The WHO-recommended First-line Treatment of Severe Malaria

    Artesun® has saved over 48 million severe malaria patients worldwide, mostly African children under the age of five.

  • Han Li Kang (Rituximab Injection)

    First China-developed Biosimilar

    Since its approval in 2019, Han Li Kang has benefited more than 100,000 patients in China

  • Han Qu You(trastuzumab, Zercepac® in the EU)

    The first China-developed mAb biosimilar approved both in China and in the EU

    Zercepac®(150mg)has been marketed in nearly 20 EU countries and regions such as England, Germany, Spain and France.

  • Han Si Zhuang (Serplulimab Injection)

    Henlius’s first self-developed innovative monoclonal antibody approved by the NMPA

  • Yi Kai Da (Axicabtagene Ciloleucel)

    China's first approved CAR-T cell therapy

    As of end of May 2022, Axicabtagene Ciloleucel has been listed in the urban Huiminbao insurance initiatives in 32 provinces and municipalities and covered by more than 50 commercial insurances.

  • Su Ke Xin (Avatrombopag Maleate Tablets)

    Fosun Pharma’s first innovative small molecule drug introduced and China’s first drug approved for CLDT treatment

    Su Ke Xin was included in the national medical insurance catalog in December 2020, and the medical insurance standard has been implemented from March 1, 2021, which comprehensively improves the accessibility of clinical treatment for patients

  • mRNA COVID-19 Vaccine COMIRNATY® (also known as BNT162b2)

    The world's first mRNA COVID-19 vaccine fully approved by FDA

  • Novel Coronavirus (2019-nCoV) Antigen Detection Kit and Novel Coronavirus (2019-nCoV) RT-PCR Detection Kit

    Fosun Diagnostics is one of the dual-certificate enterprises that have obtained the registration certificates of both Novel Coronavirus Antigen Detection Kit and Novel Coronavirus RT-PCR Detection Kit

  • Da Vinci Surgical Robots

    The first robotic surgery system approved by the FDA for general laparoscopic surgery and the most widely used laparoscopic surgery robot in the world

  • Pharmaceutical Manufacturing

  • Vaccines

  • Medical Devices

  • Medical Diagnosis

  • Healthcare Services

  • Pharmaceutical Distribution And Retail

News & Media

All News

2022-06-21

Fosun Pharma Gains BioNJ Award for Self-developed COVID-19 RT-PCR Detection Kit

(21 June 2022, Shanghai, China) During the BioNJ's 29th Annual Dinner Meeting & Innovation Celebration earlier this month, Fosun Pharma was awarded the Heart of BioNJ with the COVID-19 RT-PCR Detection Kit which was independently developed by its subsidiary company Fosun Diagnostics.

2022-06-16

Continuously Promoting Innovation and Internationalization Fosun Pharma Presents at 2022 BIO International Convention

(16 June 2022, Shanghai, China) 16 June 2022, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; Stock Code: 600196.SH, 02196.HK), a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China, announced that Fosun Pharma presents a corporate overview at the BIO International Convention, which was held from June 13 to 16, 2022 at the San Diego Convention Center in California, USA.

2022-05-25

Axicabtagene Ciloleucel - Fosun Kite's CAR-T Cell Therapy Approved to be Included in the 2022 Version of Shanghai “Huhuibao”

(Shanghai, China on May 25, 2022) On May 25, 2022, the 2022 version of Shanghai’s urban customized commercial supplementary medical insurance “Huhuibao” was officially launched for pre-sale. In this year, the premium is priced at RMB 129/year, with a total coverage of RMB 3.1 million, and the new version of “Huhuibao” covers a wider range of participants and updated liability coverage.

Stock Quote

Dual-Listed on A+H Shares

Sustainable Development

In Pursuit of Sustainable Development of Talents and Products

Fosun Pharma adheres to the concept of "pursuing sustainable development of talents and products", comprehensively practices corporate social responsibility, continuously improves the satisfaction of stakeholders, and is committed to leading the development of social responsibility in the industry.

XML 地图 | Sitemap 地图